TrovaGene Inc  

(Public, NASDAQ:TROVU)   Watch this stock  
Find more results for TROVU
0.00 (0.00%)
Mar 25 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 13.35 - 25.00
Open     -
Vol / Avg. 0.00/10.00
Mkt cap 94.70M
P/E     -
Div/yield     -
EPS -0.68
Shares 6.29M
Beta     -
Inst. own 70%
Feb 13, 2014
TrovaGene Inc at Leerink Swann Global Healthcare Conference
Feb 11, 2014
TrovaGene Inc at Biotechnology Industry Organization CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -2172.09% -4555.81%
Operating margin -6014.21% -4123.64%
EBITD margin - -4073.30%
Return on average assets -14.66% -60.85%
Return on average equity -20.05% -104.97%
Employees 14 -
CDP Score - -


United States - Map
+1-858-2175420 (Phone)
+1-858-2174768 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


TrovaGene, Inc. (TrovaGene) is a development-stage molecular diagnostic company that focuses on the development and marketing of urine-based nucleic acid tests for patient/disease screening and monitoring. The Company's novel tests predominantly use transrenal DNA (Tr-DNA) and transrenal RNA (Tr-RNA). The Company's technology is used to all transrenal nucleic acids (Tr-NA). The Company�s urine-based test addresses market needs, such as women�s healthcare-fetal medicine-down syndrome, infectious diseases, cancer testing, transplantation, drug development and monitoring of therapeutic outcomes, ultra-sensitive analytical and detection system, technologies for the collection, shipment and storage of urine specimens, and transrenal nucleic acid extraction, and instrumentation/system platform. On February 1, 2012, the Company acquired the clinical laboratory improvement amendments (CLIA) laboratory assets of MultiGEN Diagnostics, Inc. (MultiGEN).

Officers and directors

Thomas H. Adams Jr., Ph.D. Independent Chairman of the Board
Age: 70
Bio & Compensation  - Reuters
Antonius P. Schuh Ph.D. Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Stephen L. Zaniboni Chief Financial Officer
Age: 55
Bio & Compensation  - Reuters
Paul R. Billings Director
Bio & Compensation  - Reuters
Gabriele M. Cerrone Director
Age: 41
Bio & Compensation  - Reuters
Rodney S. Markin M.D., Ph.D. Director
Age: 56
Bio & Compensation  - Reuters
John P. Brancaccio Independent Director
Age: 65
Bio & Compensation  - Reuters
Gary S. Jacob Ph.D. Independent Director
Age: 66
Bio & Compensation  - Reuters